Koninklijke Philips (NYSE:PHG) Rating Increased to Strong-Buy at Sanford C. Bernstein

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by Sanford C. Bernstein from a "hold" rating to a "strong-buy" rating in a research report issued on Tuesday, March 18th,Zacks.com reports.

A number of other research analysts have also weighed in on the stock. StockNews.com raised shares of Koninklijke Philips from a "hold" rating to a "buy" rating in a research note on Saturday, March 8th. UBS Group raised Koninklijke Philips from a "neutral" rating to a "buy" rating in a research note on Thursday, February 20th. Finally, BNP Paribas raised Koninklijke Philips from a "neutral" rating to an "outperform" rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy".

Koninklijke Philips Price Performance

Shares of PHG traded up $0.02 during trading hours on Tuesday, hitting $25.47. 967,604 shares of the stock were exchanged, compared to its average volume of 868,162. The stock's 50-day moving average price is $26.73 and its two-hundred day moving average price is $27.68. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. The company has a market cap of $23.94 billion, a price-to-earnings ratio of -30.32, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. Koninklijke Philips has a 12-month low of $19.10 and a 12-month high of $32.91.

Remove Ads

Koninklijke Philips (NYSE:PHG - Get Free Report) last issued its earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts' consensus estimates of $0.55 by ($0.01). The business had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. Research analysts expect that Koninklijke Philips will post 1.63 earnings per share for the current year.

Institutional Investors Weigh In On Koninklijke Philips

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Koninklijke Philips by 9.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 99,003 shares of the technology company's stock worth $2,507,000 after purchasing an additional 8,526 shares during the period. Forum Financial Management LP lifted its position in Koninklijke Philips by 18.0% in the fourth quarter. Forum Financial Management LP now owns 11,703 shares of the technology company's stock valued at $296,000 after buying an additional 1,784 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new position in Koninklijke Philips during the fourth quarter worth about $114,000. Vise Technologies Inc. increased its position in shares of Koninklijke Philips by 50.9% during the fourth quarter. Vise Technologies Inc. now owns 14,224 shares of the technology company's stock valued at $360,000 after acquiring an additional 4,795 shares during the last quarter. Finally, Vident Advisory LLC raised its stake in shares of Koninklijke Philips by 6.4% in the 4th quarter. Vident Advisory LLC now owns 36,788 shares of the technology company's stock valued at $932,000 after acquiring an additional 2,210 shares during the period. Institutional investors and hedge funds own 13.67% of the company's stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.